Navigation Links
Eaton Scientific Systems, Ltd. completes its Study Protocol for its Planned Clinical Trial of its Patent Pending Non-Hormonal Treatment of Hot Flashes.
Date:9/6/2012

BEVERLY HILLS, Calif., Sept. 6, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton" or the "Company") a wholly-owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that it has completed the Protocol for the Clinical Trial for Tropine 3, its novel indication of homatropine, in oral suspension to be prescribed to women afflicted with hot flashes during pre-menopause, peri-menopause, and post-menopause. 

Eaton CEO, Michael Borkowski, announced today that Eaton has a complete Protocol that is the guideline for Eaton's Clinical Trial. "This is a very important step in the process of seeking FDA Approval for Tropine 3 and illustrates our progress towards the Clinical Trial."

The Protocol and proposed Clinical Trial will be a Phase I/II, Prospective, Randomized, Double Blind, Placebo-Controlled, Dose Escalation, Open Label Study to Test the Efficacy and Safety of Homatropine Methylbromide Oral Suspension on Selected Climacteric Symptoms and Quality of Life in Menopausal Women Not Receiving HRT.

Homatropine methylbromide has been used as a drug in humans for over 50 years.  Currently, it is used to discourage overdose in the popular narcotic cough syrup Hycodan.

Due to the long established use of homatropine methylbromide, the usual bench toxicity and animal studies will not be performed for this IND application.  Instead, a combined phase I/II design will be used.  This design incorporates both dose-finding rules and early stopping rules in terms of response and toxicity, thus combining elements of more typical Phase I and Phase II designs.

About Pristine Solutions, Inc.
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.   

Forward-Looking Statements/Disclaimer

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.


'/>"/>
SOURCE Eaton Scientific Systems, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
2. Pristine Solutions, Inc. Completes Acquisition of Eaton Scientific Systems, Ltd. - Enters Multi-Billion Dollar Womens Health and Drug Sector
3. Eaton Scientific Systems Confirms Acquisition and Status of Tropine 3 Patent Pending Non-Hormonal Treatment of Hot Flashes in Menopausal Women
4. Eaton Scientific Announces Clinical Trial Plans for Tropine 3 - Company to Seek FDA Approval as Novel Prescription Drug for Non-Hormonal Treatment of Hot Flashes in Menopausal Women
5. Eaton Scientific Discusses Positive Anecdotal Feedback from Pharmacist Compounding Homatropine for Doctors Treating Patients Experiencing Hot Flash Symptoms in the Beverley Hills and Los Angeles Area.
6. Eaton Scientific Enters Agreement with RoxSan Pharmacy to Provide Tropine 3 for its upcoming Clinical Trial Participants
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
9. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
10. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
11. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Australia Glaucoma Surgery Devices Market ... report, "Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices market. The report provides value, ... and average prices (USD) within market segement - ... company shares and distribution shares data for each ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized ... Top Workplaces National Standard. To learn more about ... ... Inc.) ... survey administered by WorkplaceDynamics, LLC, a research firm specializing in organizational ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic Trainers’ ... during the summer of 2016. The program was made possible by a Pennsylvania ... Department of Health and Human Services Administration. The broadcast, Use Your Head: ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce ... service for Texas, they are expanding their presence in Dallas. One of the most ... will bring new jobs to the Dallas and Forth Worth market. STAT takes pride ...
Breaking Medicine News(10 mins):